Turning gray: The natural history of lung cancer over time

Journal of Thoracic Oncology

Volumn 3, Issue 7, 2008, Pages 781-792

  Detterbeck, Frank C ^a,c   Gibson, Christopher J ^b  

^a YALE CANCER CENTER   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NONE   (United States)

Author keywords

Doubling time; Lung cancer; Natural history; Screening

Indexed keywords

ANTIBIOTIC AGENT;

CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER REGISTRY; CANCER SCREENING; CANCER SURVIVAL; CLINICAL ASSESSMENT; CLINICAL FEATURE; CLINICAL TRIAL; COHORT ANALYSIS; COMORBIDITY; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DISEASE COURSE; DISEASE SEVERITY; EVIDENCE BASED PRACTICE; GROWTH; HEALTH CARE DELIVERY; HEALTH PROGRAM; HISTORY; HUMAN; INFECTION; LIFE; LUNG; LUNG ADENOCARCINOMA; LUNG ALVEOLUS CELL CARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG RESECTION; MEDICAL CARE; NONHUMAN; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SHORT SURVEY; SURVIVAL RATE; SYSTEMATIC REVIEW; THORAX RADIOGRAPHY; TREATMENT OUTCOME; TUMOR GROWTH; TUMOR VOLUME; ANIMAL; LUNG TUMOR; MORTALITY; PATHOLOGY; PROGNOSIS; REVIEW;

ANIMALS; HUMANS; LUNG NEOPLASMS; PROGNOSIS; SURVIVAL RATE;

EID: 50349097755     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e31817c9230     Document Type: Article

References (78)

1. Henschke C, Yankelevitz D, Libby DM, et al. Survival of patients with stage I lung cancer detected on CT screening. N Engl J Med 2006;355: 1763-1771.
2. Onishi H, Nagata Y, Shirato H, et al. Stereotactic hypofractionated high-dose irradiation for stage I non-small cell lung carcinoma: clinical outcomes in 273 cases of a Japanese multi-institutional study. ASCO 2004;22; abstract no. 7003.
3. Yellen SB, Cella DF. Someone to live for: social well-being, parenthood status, and decision-making in oncology. J Clin Oncol 1995;13:1255- 1264.
4. Battafarano RJ, Piccirillo JF, Meyers BF, et al. Impact of comorbidity on survival after surgical resection in patients with stage I non-small cell lung cancer. J Thorac Cardiovasc Surg 2002;123:280-287.
5. Stinchcombe TE, Socinski MA. General aspects of chemotherapy. In Detterbeck FC, Rivera MP, Socinski MA, Rosenman JG, (Eds.), Diagnosis and Treatment of Lung Cancer: An Evidence-Based Guide for the Practicing Clinician. Philadelphia, PA: WB Saunders, 2001. Pp. 162- 173.
6. Weed DL. Methodologic guidelines for review papers. J Natl Cancer Inst 1997;89:6-7.
7. Moher D, Tetzlaff J, Tricco AC, Sampson M, Altman DG. Epidemiology and reporting characteristics of systematic reviews. PLoS Med 2007;4:e78.
8. Socinski MA, Morris DE, Masters GA, Lilenbaum R. Chemotherapeutic management of stage IV non-small cell lung cancer. Chest 2003;123: 226S-243S.
9. Socinski MA, Crowell R, Hensing TE, et al. Treatment of non-small cell lung cancer, stage IV: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007;132:277S-289S.
10. Satariano W, Ragland K, Van Den Eeden S. Cause of death in men diagnosed with prostate carcinoma. Cancer 1998;83:1180-1188.
11. Penson DF, Albertsen PC, Nelson PS, Barry M, Stanford JL. Determining cause of death in prostate cancer: are death certificates valid? J Natl Cancer Inst 2001;93:1822-1823.
12. Albertsen PC, Walters S, Hanley JA. A comparison of cause of death determination in men previously diagnosed with prostate cancer who died in 1985 or 1995. J Urol 2000;163:519-523.
13. Sobue T, Suzuki T, Matsuda M, et al. Survival for clinical stage I lung cancer not surgically treated: comparison between screen-detected and symptom-detected cases. Cancer 1992;69:685-692.
14. Motohiro A, Ueda H, Komatsu H, Yanai N, Mori T. Prognosis of non-surgically treated, clinical stage I lung cancer patients in Japan. Lung Cancer 2002;36:65-69.
15. Flehinger BJ, Kimmel M, Melamed MR. The effect of surgical treatment on survival from early lung cancer: implications for screening. Chest 1992;101:1013-1018.
16. Hasegawa M, Sone S, Takashima S, et al. Growth rate of small lung cancers detected on mass CT screening. Br J Radiol 2000;73:1252- 1259.
17. Lindell RM, Hartman TE, Swensen SJ, et al. Five-year lung cancer screening experience: CT appearance, growth rate, location, and histo-logic features of 61 lung cancers. Radiology 2007;242:555-562.
18. Sone S, Nakayama T, Honda T, et al. Long-term follow-up study of a population-based 1996-1998 mass screening programme for lung cancer using mobile low-dose spiral computed tomography. Lung cancer 2007;58:329-341.
19. Usuda K, Saito Y, Sagawa M, et al. Tumor doubling time and prognostic assessment of patients with primary lung cancer. Cancer 1994;74:2239- 2244.
20. Wisnivesky JP, Halm EA. Sex differences in lung cancer survival: do tumors behave differently in elderly women? J Clin Oncol 2007;25: 1705-1712.
21. Winer-Muram HT, Jennings SG, Tarver RD, et al. Volumetric growth rate of stage I lung cancer prior to treatment: serial CT scanning. Radiology 2002;223:798-805.
22. Skipper HE, Schabel FM Jr, Wilcox WS. On the criteria and kinetics associated with "curability" of experimental leukemia. Cancer Chemother Rep 1964;35:1-111.
23. Bach PB, Silvestri G, Hanger M, Jett JR. Screening for lung cancer: ACCP evidence-based clincial practice guidelines, (2nd edition). Chest 2007;132:69S-77S.
24. Steele JD, Buell P. Asymptomatic solitary pulmonary nodules: host survival, tumor size, and growth rate. J Thorac Cardiovasc Surg 1973; 65:140-151.
25. Spratt J, Spratt T. Rates of growth of pulmonary metastases and host survival. Ann Surg 1964;159:161-171.
26. Weiss W. Peripheral measurable bronchogenic carcinoma. Growth rate and period of risk after therapy. Am Rev Respir Dis 1971;103:198-208.
27. DeVita VT Jr. Principles of cancer management: chemotherapy. In: DeVita VT Jr, Hellman S, Rosenberg SA, (Eds.), Cancer: Principles & Practice of Oncology, 5th Ed. Philadelphia: Lippincott-Raven, 1997. Pp. 333-347.
28. Schabel FM Jr. Concepts for systemic treatment of micrometastases. Cancer 1975;35:15-24.
29. Norton L. A Gompertzian model of human breast cancer growth. Cancer Res 1988;48:7067-7071.
30. Gunduz N, Fisher B, Saffer EA. Effect of surgical removal on the growth and kinetics of residual tumor. Cancer Res 1979;39:3861-3865.
31. Simpson-Herrin L, Sanford AH, Holmquist JP. Effects of surgery in the cell kinetics of residual tumor. Cancer Treat Rep 1976;60:1744-1760.
32. Peck K, Sher Y-P, Shih J-Y, et al. Detection and quantitation of circulating cancer cells in the peripheral blood of lung cancer patients. Cancer Res 1998;58:2761-2765.
33. Mizuno T, Masaoka A, Ichimura H, et al. Comparison of actual survivorship after treatment with survivorship predicted by actual tumor-volume doubling time from tumor diameter at first observation. Cancer 1984;53:2716-2720.
34. Geddes DM. The natural history of lung cancer: a review based on rates of tumour growth. Br J Dis Chest 1979;73:1-17.
35. McGarry RC, Song G, des Rosiers P, Timmerman R. Observation-only management of early stage, medically inoperable lung cancer: poor outcome. Chest 2002;121:1155-1158.
36. Raz DJ, Zell JA, Ou SHI, et al. Natural history of stage I non-small cell lung cancer: implications for early detection. Chest 2007;132:193-199.
37. Altorki N, Kent M, Pasmantier M. Detection of early-stage lung cancer: computed tomographic scan or chest radiograph? J Thorac Cardiovasc Surg 2001;121:1053-1057.
38. Kashiwabara K, Kohshi S. Outcome in patients with lung cancer invisible on chest roentgenograms but detected only by helical computed tomography. Respirology 2006;11:592-597.
39. Kashiwabara K, Koshi S, Ota K, Tanaka M, Toyonaga M. Outcome in patients with lung cancer found retrospectively to have had evidence of disease on past lung cancer mass screening roentgenograms. Lung Cancer 2002;35:237-241.
40. Kashiwabara K, Koshi S, Itonaga K, et al. Outcome in patients with lung cancer found on lung cancer mass screening roentgenograms, but who did not subsequently consult a doctor. Lung Cancer 2003;40:67-72.
41. Lindell RM, Hartman TE, Swensen SJ, et al. Lung cancer screening experience: a retrospective review of PET in 22 non-small cell lung carcinomas detected on screening chest CT in a high-risk population. Am J Roentgenol 2005;185:126-131.
42. Sobue T, Moriyama N, Kaneko M, et al. Screening for lung cancer with low-dose helical computed tomography: anti-lung cancer association project. J Clin Oncol 2002;20:911-920.
43. Sone S, Takashima S, Li F, et al. Mass screening for lung cancer with mobile spiral computed tomography scanner. Lancet 1998;351:1242- 1245.
44. Pastorino U, Bellomi M, Landoni C, et al. Early lung-cancer detection with spiral CT and positron emission tomography in heavy smokers: 2-year results. Lancet 2003;362:593-597.
45. Swensen SJ, Jett JR, Hartman TE, et al. CT screening for lung cancer: five-year prospective experience. Radiology 2005;235:259-265.
46. Spiro SG, Gould MK, Colice GL. Initial evaluation of the patient with lung cancer: symptoms, signs, laboratory tests, and paraneoplastic syndromes: ACCP evidenced-based clinical practice guidelines, (2nd edition). Chest 2007;132:149S-160S.
47. Alberts WM, Bepler G, Hazelton T, Ruckdeschel JC, Williams JH Jr. Lung cancer. Practice organization. Chest 2003;123:332S-337S.
48. BTS. BTS recommendations to respiratory physicians for organising the care of patients with lung cancer. Thorax 1998;53:S1-S8.
49. Hillner BE, Smith TJ, Desch CE. Hospital and physician volume or specialization and outcomes in cancer treatment: importance in quality of cancer care. J Clin Oncol 2000;18:2327-2340.
50. Silvestri GA, Handy J, Lackland D, Corley E, Reed CE. Specialists achieve better outcomes than generalists for lung cancer surgery. Chest 1998;114:675-680.
51. Bach PB, Cramer LD, Schrag D, et al. The influence of hospital volume on survival after resection for lung cancer. N Engl J Med 2001;345:181- 188.
52. Fergusson RJ, Thomson CS, Brewster DH, et al. Lung cancer: the importance of seeing a respiratory physician. Eur Respir J 2003;21:606- 610.
53. Smith TJ, Hillner BE. Ensuring quality cancer care by the use of clinical practice guidelines and critical pathways. J Clin Oncol 2001;19:2886- 2897.
54. Ikeda K, Awai K, Mori T, et al. Differential diagnosis of ground-glass opacity nodules: CT number analysis by three-dimensional computerized quantification. Chest 2007;132:984-990.
55. Kim H, Shim Y, Lee K, et al. Persistent pulmonary nodular ground-glass opacity at thin-section CT: histopathologic comparisons. Radiology 2007;245:267-275.
56. Ohtsuka T, Watanabe K, Kaji M, Naruke T, Suemasu K. A clinicopath-ological study of resected pulmonary nodules with focal pure ground-glass opacity. Eur J CardioThorac Surg 2006;30:160-163.
57. Takashima S, Maruyama Y, Hasegawa M, et al. CT findings and progression of small peripheral lung neoplasms having a replacement growth pattern. AJR Am J Roentgenol 2003;180:817-826.
58. Kakinuma R, Ohmatsu H, Kaneko M, et al. Progression of focal pure ground-glass opacity detected by low-dose helical computed tomography screening for lung cancer. J Comput Assist Tomogr 2004;28:17-23.
59. Jennings SG, Winer-Muram HT, Tann M, Ying J, Dowdeswell I. Distribution of stage I lung cancer growth rates determined with serial volumetric CT measurements. Radiology 2006;241:554-563.
60. Brenner DJ, Hall EJ. Computed tomography - an increasing source of radiation exposure. N Engl J Med 2007;357:2277-2284.
61. Hanagiri T, Sugio K, Mizukami M, et al. Postoperative prognosis in patients with non-small cell lung cancer according to the method of initial detection. J Thorac Oncol 2007;2:907-911.
62. Hyde L, Yee J, Wilson R, Patno M. Cell type and the natural history of lung cancer. JAMA 1965;193:140-142.
63. Roswit B, Patno ME, Rapp R, et al. The survival of patients with inoperable lung cancer: a large-scale randomized study of radiation therapy versus placebo. Radiology 1968;90:688-697.
64. Hyde L, Wolf J, McCracken S, Yesner R. Natural course of inoperable lung cancer. Chest 1973;64:309-312.
65. Zelen M. Keynote address on biostatistics and data retrieval. Cancer Chemother Rep 3 1973;4:31-42.
66. Paul A, Marelli D, Wilson JAS, Chiu RC, Mulder DS. Does the surgical trauma of "exploratory thoracotomy" affect survival of patients with bronchogenic carcinoma? Can J Surg 1989;32:322-327.
67. Reinfuss M, Skolyszewski J, Kowalska T, Rzepecki W, Kociolek D. Palliative radiotherapy in asymptomatic patients with locally advanced, unresectable, non-small cell lung cancer. Strahlenther Onkol 1993;169: 709-715.
68. Vrdoljak E, Mise K, Sapunar D, Rozga A, Marusic M. Survival analysis of untreated patients with non-small-cell lung cancer. Chest 1994;106: 1797-1800.
69. Leung WT, Shiu WCT, Pang JCK, et al. Combined chemotherapy and radiotherapy versus best supportive care in the treatment of inoperable non-small-cell lung cancer. Oncology 1992;49:321-326.
70. Chadha A, Ganti A, Sohi J, Sahmoun A, Mehdi SA. Survival in untreated early stage non-small cell lung cancer. Anticancer Res 2005; 25:3517-3520.
71. Kyasa MJ, Jazieh AR. Characteristics and outcomes of patients with unresected early-stage non-small cell lung cancer. South Med J 2002; 95:1149-1152.
72. Henschke CI, Wisnivesky JP, Yankelevitz DF, Miettinen OS. Small stage I cancers of the lung: genuineness and curability. Lung Cancer 2003;39:327-330.
73. Wisnivesky JP, Bonomi M, Henschke C, Iannuzzi M, McGinn T. Radiation therapy for the treatment of unresected stage I-II non-small cell lung cancer. Chest 2005;128:1461-1467.
74. Garland LH, Coulson W, Wollin E. The rate of growth and apparent duration of untreated primary bronchial carcinoma. Cancer 1963;16: 694-707.
75. Arai T, Kuroishi T, Saito Y, et al. Tumor doubling time and prognosis in lung cancer patients: evaluation from chest films and clinical follow-up study. Jpn J Clin Oncol 1994;24:199 -204.
76. Yankelevitz DF, Kostis WJ, Henschke CI, et al. Overdiagnosis in chest radiographic screening for lung carcinoma: frequency. Cancer 2003;97: 1271-1275.
77. Weiss W, Boucot K, Cooper D. Growth rate in the detection and prognosis of bronchogenic carcinoma. JAMA 1966;198:1246-1252.
78. Kerr K, Lamb D. Actual growth rate and tumour cell proliferation in human pulmonary neoplasms. Br J Cancer 1984;50:343-349.